Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H18N2O4 |
Molecular Weight | 362.3786 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(O)CC(=O)OCC2=C1C=C3N(CC4=CC5=CC=CC=C5N=C34)C2=O
InChI
InChIKey=PAEZRCINULFAGO-UHFFFAOYSA-N
InChI=1S/C21H18N2O4/c1-2-21(26)9-18(24)27-11-14-15(21)8-17-19-13(10-23(17)20(14)25)7-12-5-3-4-6-16(12)22-19/h3-8,26H,2,9-11H2,1H3
Molecular Formula | C21H18N2O4 |
Molecular Weight | 362.3786 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
E-Homocamptothecin, (±)- (also known as BN 80245) is an E-ring modified analog of camptothecin. This compound is more stable than camptothecin, remains a potent inhibitor of both cell growth and topoisomerase I. Homocamptothecin exhibited high in vitro cytotoxicities and good in vivo efficacy, thus that compound could be a promising template for the preparation of improved anticancer agents.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P11387|||Q9UJN0 Gene ID: 7150.0 Gene Symbol: TOP1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9876111 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. | 1998 Dec 31 |
|
Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. | 1999 Jun 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10383158
The mouse L1210 lymphoblastic leukemia cells were maintained by serial i.p. passage in DBA/2 mice: when injected i.p. daily for 4 days, racemic homocamptothecin (dl-hCPT) increased the life span of the mice (untreated animals died between day 9 and day 14 posttumor-cell injection) treated at doses ranging from 0.32 to 2.5 mg/kg, with maximal efficacy at 1.25 mg/kg.
Route of Administration:
Intraperitoneal
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:35:30 GMT 2023
by
admin
on
Sat Dec 16 08:35:30 GMT 2023
|
Record UNII |
33SH2P87CX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9863779
Created by
admin on Sat Dec 16 08:35:30 GMT 2023 , Edited by admin on Sat Dec 16 08:35:30 GMT 2023
|
PRIMARY | |||
|
33SH2P87CX
Created by
admin on Sat Dec 16 08:35:30 GMT 2023 , Edited by admin on Sat Dec 16 08:35:30 GMT 2023
|
PRIMARY | |||
|
186668-40-6
Created by
admin on Sat Dec 16 08:35:30 GMT 2023 , Edited by admin on Sat Dec 16 08:35:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |